Health
MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors at SITC 2025
Durable survival and deep, lasting remissions in checkpoint-refractory, heavily pretreated cancers with median OS of ~23 months with agenT-797 plus anti-PD-1Evidence of immune activation and tumor-immune remodeling underscore agenT-797’s potential to restore responsiveness in PD-1–resistant diseaseFavorable safety and reproducible activity reinforce MiNK’s leadership in allogeneic iNKT cell therapy NEW YORK, Nov. 07, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-sta
About this update from Mink Therapeutics, Inc.
[{"type":"image","alt":"MiNK Therapeutics","displaySize":"","headline":null,"caption":"MiNK Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":116,"url":"https://media.zenfs.com/en/globenewswire.com/4b1b28678bcbc056b777d0ad1341f645"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/zvDa2P.MLQrfKYIZ2UPPSQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2MjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/4b1b28678bcbc056b777d0ad1341f645","width":300,"height":116}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Durable survival and deep, lasting remissions in checkpoint-refractory, heavily pretreated cancers with median OS of ~23 months with agenT-797 plus anti-PD-1","length":157,"tagName":"p"}]},{"val":[{"type":"text","content":"Evidence of immune activation and tumor-immune remodeling underscore agenT-797’s potential to restore responsiveness in PD-1–resistant disease","length":142,"tagName":"p"}]},{"val":[{"type":"text","content":"Favorable safety and reproducible activity reinforce MiNK’s leadership in allogeneic iNKT cell therapy","length":102,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":401,"olType":false},{"type":"text","content":"NEW YORK, Nov. 07, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell therapies to reconstitute immunity to treat cancer and immune disorders, today announced updated clinical results evaluating agenT-797, alone and in combination with anti-PD-1 therapy, in patients with advanced solid tumors refractory to all approved treatments presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025 (Late Breaking Abstract #1344).","length":566,"tagName":"p"},{"type":"text","content":"The results demonstrate durable survival, deep and lasting responses, and broad immune restoration in patients with solid tumors that had progressed on checkpoint inhibitors and multiple prior therapies.","length":203,"tagName":"p"},{"type":"text","content":"“We’re seeing encouraging clinical activity with agenT-797 — including durable responses and deep remissions that have persisted beyond two years in some patients,” said Dr. Ben Garmezy, Associate Director of Genitourinary Research at Sarah Cannon Research Institute and pres...